二肽基肽酶-4抑制剂对2型糖尿病患者白细胞介素水平的影响
该系统评价与荟萃分析纳入14项随机对照试验共850名参与者,评估二肽基肽酶-4抑制剂对2型糖尿病患者白细胞介素浓度的影响。汇总结果显示,与安慰剂相比,二肽基肽酶-4抑制剂显著降低白细胞介素-6浓度(-0.54 pg/mL;95%CI,-0.82至-0.25;I²=10%,P=.0003),对白细胞介素-1β也有类似效果(-16.33 pg/mL;95%CI,-19.56至-13.11;I²=0%,P<.00001),但对白细胞介素-18的影响无统计学显著差异(-13.55 pg/mL;95%CI,-76.95至49.85;I²=0%,P=.68)。作者结论认为二肽基肽酶-4抑制剂有利地降低2型糖尿病患者的白细胞介素-6水平,其对白细胞介素-1β和白细胞介素-18的影响需更多研究探索,需进一步试验阐明该抗炎效应。
要点
- 与安慰剂相比,二肽基肽酶-4抑制剂显著降低2型糖尿病患者白细胞介素-6浓度(-0.54 pg/mL;95%CI,-0.82至-0.25;P=.0003)。
- 二肽基肽酶-4抑制剂对白细胞介素-1β有类似降低效果(-16.33 pg/mL;95%CI,-19.56至-13.11;P<.00001)。
- 对白细胞介素-18的影响无统计学显著差异(-13.55 pg/mL;95%CI,-76.95至49.85;P=.68)。
核心结论
- 二肽基肽酶-4抑制剂有利地降低2型糖尿病患者的白细胞介素-6水平。
- 二肽基肽酶-4抑制剂对白细胞介素-1β和白细胞介素-18的影响需更多研究探索。
- 需进一步试验阐明二肽基肽酶-4抑制剂治疗2型糖尿病期间的抗炎效应。
研究设计与样本
- 系统评价与荟萃分析,系统检索PubMed、Embase和Cochrane图书馆从建库至2024年5月31日的相关文献。
- 纳入14项随机对照试验,共850名参与者,均为安慰剂或活性药物对照的人体研究。
主要发现
- 与安慰剂相比,二肽基肽酶-4抑制剂显著降低白细胞介素-6浓度(-0.54 pg/mL;95%CI,-0.82至-0.25;I²=10%,P=.0003)。
- 二肽基肽酶-4抑制剂对白细胞介素-1β有类似效果(-16.33 pg/mL;95%CI,-19.56至-13.11;I²=0%,P<.00001)。
- 对白细胞介素-18的影响无统计学显著差异(-13.55 pg/mL;95%CI,-76.95至49.85;I²=0%,P=.68)。
- 白细胞介素-6亚组分析显示,在基线白细胞介素-6浓度<5 pg/mL组、体重指数≥28 kg/m²组和DPP-4i类型为利格列汀组中观察到显著效果。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Accumulating evidence had implicated pathological involvement of interleukins (ILs) in progression and complications in patients with type 2 diabetes mellitus (T2DM). Dipeptidyl peptidase-4 inhibitors (DPP-4i) produced favorable effects on glucose homeostasis in T2DM. This study aimed to evaluate the impact of DPP-4i on IL concentrations in T2DM. DATA SOURCES: PubMed, Embase, and the Cochrane library were systematically searched for relevant articles from inception to May 31, 2024. The search included DPP-4i, T2DM, and randomized controlled trials (RCTs) and related terms. STUDY SELECTION AND DATA EXTRACTION: Placebo- or active agents-controlled human studies were screened. All the RCTs were identified if they provided detailed information on changes of ILs during DPP-4i treatment. DATA SYNTHESIS: A total of 14 RCTs involving 850 participants were identified. Pooled estimates revealed that DPP-4i significantly lowered IL-6 concentrations (-0.54 pg/mL; 95% CI, -0.82 to -0.25; I2 = 10%, P = .0003) compared to placebo. Similar effects were demonstrated for IL-1β (-16.33 pg/mL; 95% CI, -19.56 to -13.11; I2 = 0%, P < .00001), whereas the effect on IL-18 was not statistically significant (-13.55 pg/mL; 95% CI, -76.95 to 49.85; I2 = 0%, P = .68). Subgroup analysis on IL-6 demonstrated that marked effects were found in groups of basal IL-6 concentrations (< 5 pg/mL), body mass index (≥ 28 kg/m2) and type of DPP-4i (linagliptin). CONCLUSION: DPP-4i favorably decreased IL-6 levels in patients with T2DM. The impact of DPP-4i on IL-1β and IL-18 needed to be explored with more studies. Further trials should be performed to elucidate this anti-inflammatory effect of DPP-4i during treatment of T2DM.
引用
- Feng Y, Shang B, Yang Y, et al. Impact of DPP-4 Inhibitors on Interleukin Levels in Type 2 Diabetes Mellitus. J Clin Endocrinol Metab. 2025. PMID: 39512193. doi:10.1210/clinem/dgae783
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。